BiotechTube

Pneumococcal protein vaccine + Pneumococcal protein vaccine + Pneumococcal protein vaccine + Pneumococcal protein vaccine + Pneumococcal protein vaccine

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Adverse Effects

Conditions

Adverse Effects

Trial Timeline

Sep 1, 2011 → Feb 1, 2014

NCT ID
NCT01764126

About Pneumococcal protein vaccine + Pneumococcal protein vaccine + Pneumococcal protein vaccine + Pneumococcal protein vaccine + Pneumococcal protein vaccine

Pneumococcal protein vaccine + Pneumococcal protein vaccine + Pneumococcal protein vaccine + Pneumococcal protein vaccine + Pneumococcal protein vaccine is a phase 1 stage product being developed by Sanofi for Adverse Effects. The current trial status is completed. This product is registered under clinical trial identifier NCT01764126. Target conditions include Adverse Effects.

What happened to similar drugs?

1 of 2 similar drugs in Adverse Effects were approved

Approved (1) Terminated (0) Active (1)
✅Vaccination with ACAM2000Emergent BioSolutionsApproved
🔄ACAM2000Emergent BioSolutionsPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01764126Phase 1Completed

Competing Products

7 competing products in Adverse Effects

See all competitors
ProductCompanyStageHype Score
ABT-143 + ABT-335 and rosuvastatinAstraZenecaPhase 1
29
Albuterol Sulfate + Nicardipine Hydrochloride + Dobutamine Hydrochloride + Phenylephrine Hydrochloride + Verapamil Hydrochloride + Phentolamine Mesylate + PlaceboAstraZenecaPhase 1
21
AZD1222AstraZenecaPre-clinical
26
ABT-143 + ABT-335 + RosuvastatinAstraZenecaPhase 1
29
dupilumabSanofiPre-clinical
33
ACAM2000Emergent BioSolutionsPhase 3
30
Vaccination with ACAM2000Emergent BioSolutionsApproved
33